Selection of spiking materials for studies on the clearance of agents of transmissible spongiform encephalopathy during plasma fractionation

Biologicals

Volumn 36, Issue 2, 2008, Pages 142-143

  Foster, Peter R ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

Clearance; Plasma fractionation; Prion agents; TSE agents; TSE preparations; Variant CJD

Indexed keywords

BIOMATERIAL;

BRAIN TISSUE; CREUTZFELDT JAKOB DISEASE; CRYOPRECIPITATION; FRACTIONATION; HUMAN; ION EXCHANGE CHROMATOGRAPHY; LETTER; MEDICAL RESEARCH; NANOFILTRATION; PHYSICAL CHEMISTRY; PLASMA; PRION DISEASE; PRIORITY JOURNAL; SPIKE WAVE; VIRUS INFECTIVITY; VIRUS TITRATION;

CHEMICAL FRACTIONATION; CREUTZFELDT-JAKOB SYNDROME; HUMANS; PLASMA; PRION DISEASES; PRIONS; SAFETY;

EID: 39549096455     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2007.02.001     Document Type: Letter

References (13)

1. Committee for Medicinal Products for Human Use. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. EMEA/CPMP/BWP/2879/02/rev 1 (23 June 2004), European Medicines Agency, London
2. Committee for Medicinal Products for Human Use. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. EMEA/CPMP/BWP/CPMP/5136/03 (21 October 2004), European Medicines Agency, London
3. Foster P.R. Removal of TSE agents from blood products. Vox Sang 87 Suppl. 2 (2004) 7-10
4. Vey M., Baron H., Weimer T., and Gröner A. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 30 (2002) 187-196
5. Berardi V.A., Cardone F., Valanzano A., Lu M., and Pocchiari M. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study clearance of transmissible spongiform encephalopathy agents during plasma fractionation. Transfusion 46 (2006) 652-658
6. ®). Biologicals 34 (2006) 227-231
7. Ironside J.W., and Head M.W. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 10 Suppl. 4 (2004) 64-69
8. Farshid M., Taffs R.E., Scott D., Asher D.M., and Brorson K. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Curr Opin Biotechnol 16 (2005) 561-567
9. Health Protection Agency. CJD Incidents Panel, Public summary of the 9th meeting, London, 12th June 2003. Published online at. http://hpa.org.uk/infections/topics_az/cjd/incidents_panel.htm [accessed July 2006]
10. Cervia J.S., Sowemimo-Coker S.O., Ortolano G.A., Wilkins K., Schaffer J., Wortham S.T., et al. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease. Transfus Med Rev 20 (2006) 190-206
11. Gregori L., Lambert B.C., Gurgel P.V., et al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion affinity ligands. Transfusion 46 (2006) 1152-1161
12. Gregori L., Gurgel P.V., Lathrop J.T., Edwardson P., Lambert B.C., Carbonell R.G., et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 368 (2006) 2226-2230
13. Reichl H.E., Foster P.R., Welch A.G., Li Q., MacGregor I.R., Somerville R.A., et al. Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang 83 (2002) 137-145